Tff Pharmaceuticals Inc

NASDAQ:TFFP   12:31:27 PM EDT
7.70
-0.01 (-0.13%)
Products, Regulatory, Earnings Announcements

TFF Pharmaceuticals Announces Promising Topline Results From Phase 1 Clinical Trial Of Inhaled Tacrolimus Powder

Published: 09/23/2021 12:27 GMT
Tff Pharmaceuticals Inc (TFFP) - Tff Pharmaceuticals Announces Promising Topline Results From Phase 1 Clinical Trial of Inhaled Tacrolimus Powder and Progression Toward Phase 2 in Lung Transplantation.
Tff Pharmaceuticals - Results From Trial for Tacrolimus Inhalation Powder Showed Therapeutic Drug Levels Can Be Achieved at Low Doses.
Tff Pharmaceuticals Inc - Data From Phase 1 Study Suggests That Tacrolimus Inhalation Powder Can Be Administered With an Acceptable Safety Profile.
Tff Pharmaceuticals Inc - Expects to Take Critical Steps Toward Beginning Its Phase 2 Clinical Study of Inhaled Tacrolimus Powder by End of 2021.
Revenue is expected to be $2.1 Million
Adjusted EPS is expected to be -$0.18

Next Quarter Revenue Guidance is expected to be $3.36 Million
Next Quarter EPS Guidance is expected to be -$0.17

More details on our Analysts Page.